Mechanism of Intracellular Allosteric Β2ar Antagonist Revealed by X-ray Crystal Structure
Xiangyu Liu,Seungkirl Ahn,Alem W. Kahsai,Kai-Cheng Meng,Naomi R. Latorraca,Biswaranjan Pani,A. J. Venkatakrishnan,Ali Masoudi,William I. Weis,Ron O. Dror,Xin Chen,Robert J. Lefkowitz,Brian K. Kobilka
DOI: https://doi.org/10.1038/nature23652
IF: 64.8
2017-01-01
Nature
Abstract:The authors report the crystal structure of the β2 adrenergic receptor in complex with compound 15, an allosteric modulator that binds to an alternative binding pocket. Most of the crystal structures of G-protein-coupled receptors (GPCRs) reported to date have been solved in complex with ligands bound to their orthosteric site, the primary binding site of a receptor. Recently, however, several studies have reported that certain chemokine receptors contain an allosteric pocket on their intracellular surface that could be targeted to interfere with receptor signalling. Brian Kobilka and colleagues report the crystal structure of the β2-adrenergic receptor in complex with compound 15, an allosteric modulator that binds to a similar site to the chemokine receptors, showing that this feature may be conserved among a number of GPCRs. Typically, beta-blockers, which are widely prescribed drugs for cardiac arrhythmia, block the action of the β-adrenergic receptors from the orthosteric site. This study shows how compound 15, the first allosteric beta-blocker, modulates agonist binding and signalling from its intracellular binding site. G-protein-coupled receptors (GPCRs) pose challenges for drug discovery efforts because of the high degree of structural homology in the orthosteric pocket, particularly for GPCRs within a single subfamily, such as the nine adrenergic receptors. Allosteric ligands may bind to less-conserved regions of these receptors and therefore are more likely to be selective. Unlike orthosteric ligands, which tonically activate or inhibit signalling, allosteric ligands modulate physiologic responses to hormones and neurotransmitters, and may therefore have fewer adverse effects. The majority of GPCR crystal structures published to date were obtained with receptors bound to orthosteric antagonists, and only a few structures bound to allosteric ligands have been reported. Compound 15 (Cmpd-15) is an allosteric modulator of the β2 adrenergic receptor (β2AR) that was recently isolated from a DNA-encoded small-molecule library1. Orthosteric β-adrenergic receptor antagonists, known as beta-blockers, are amongst the most prescribed drugs in the world and Cmpd-15 is the first allosteric beta-blocker. Cmpd-15 exhibits negative cooperativity with agonists and positive cooperativity with inverse agonists. Here we present the structure of the β2AR bound to a polyethylene glycol-carboxylic acid derivative (Cmpd-15PA) of this modulator. Cmpd-15PA binds to a pocket formed primarily by the cytoplasmic ends of transmembrane segments 1, 2, 6 and 7 as well as intracellular loop 1 and helix 8. A comparison of this structure with inactive- and active-state structures of the β2AR reveals the mechanism by which Cmpd-15 modulates agonist binding affinity and signalling.